Biotech Values

[Biowatch]

"EMIS labeled the mean HbA1c reduction in each trial arm as supplementary data to be released after further study rather than top-line data to be released immediately."

Agreed. One of the analysts on the conference call kept grilling them about that, but Goldberg kept dancing around the question.

The analyst kept saying. "But you must know what the data are." Goldberg kept saying they need to due further analysis and subgroup analysis, but in a few weeks they'd have it analyzed well enough to take it on the road when talking to potential big pharma partners.